This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Top 10 Buy-Rated Stocks Under $5

5. Ariad Pharmaceuticals (ARIA - Get Report) is a biotech company focused on development of targeted oncology therapies. The company's lead compound ridaforolimus is currently in a Phase III trial for sarcoma. Ariad shares have surged 62% in 2010 and are up more than 150% over the last 12 months.

Consensus: Of the analysts covering Ariad, eight, or 80%, recommend purchasing its shares and two recommend holding them.

Closing Price: $3.74 (June 2)

Bullish Case: Leerink Swan analysts have a buy rating and $6 valuation on Ariad, noting that the current ridaforolimus trial has a "good chance to be ultimately positive." The firm says that Ariad's partnership with Merck (MRK) "will supply a potentially significant royalty stream," even though "further financing may be needed to support the remaining pipeline before reaching profitability."

Bearish Scenario: Oppenheimer analysts have an outperform rating and price target of $6 for Ariad, arguing that it expects a "good probability of a positive outcome from the trial at the final analysis." The firm does note that "there could be some disappointment that the second interim analysis did not yield a positive result," although the analysts view any weakness in the stock as a buying opportunity.

6 of 10

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ARIA $9.00 -1.30%
C $54.56 -0.56%
FCEL $1.22 2.10%
MHR $1.91 0.00%
RFMD $16.59 -2.07%

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs